AstraZeneca Q4 Core Earnings Beat Estimates Despite Esing COVID Vaccine Demand0

• Uncategorized
• February 9, 2023

AstraZeneca PLC (LON:AZN) posted better-than-expected core income in the fourth quarter, thanks to strong demand for its cancer and rare disease therapies that helped make up for waning sales of its COVID-19 vaccine. Core earnings per share during the three months ended on December 31 was $1.38, a drop in actual terms of 17% compared